---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-033053"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2024-08-19T23:59:59+00:00"
generated_at: "2026-05-31T08:44:47.507775+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Provectus converts $2.13M in director fees to Series D-1 Preferred shares

## Summary
- Converted $2,131,838.75 in accrued directors’ fees into 744,878 shares of Series D-1 Preferred at $2.862 per share.
- Preferred shares are convertible into 7,448,780 shares of common stock.
- Issuance covers fees owed through September 30, 2024; not under 2024 Equity Compensation Plan.
- Board approved on August 14, 2024; fees had been accruing since April 2017.

## SEC filing metadata
- accession: 0001493152-24-033053
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2024-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315224033053/0001493152-24-033053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315224033053/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-033053
- JSON: https://secwatch.observer/filing/0001493152-24-033053.json
- Plain text: https://secwatch.observer/filing/0001493152-24-033053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.